Uncategorized | TIO Bioventures

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia

by treadwell | Apr 30, 2021 | Uncategorized

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with...

Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945

by treadwell | Dec 7, 2020 | Uncategorized

Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate,...

Treadwell Announces Initiation New Clinical Trial CFI 400945

by treadwell | Oct 19, 2020 | Uncategorized

Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer...

TIO-Bioventures-Launches-TCRyption-TCR-T-cell-based

by treadwell | Oct 8, 2020 | Uncategorized

TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based Immunotherapy...

Treadwell-Announces-Initiation-Patient-Dosing-TWT-101-Phase

by treadwell | Sep 2, 2020 | Uncategorized

Treadwell Announces Initiation of Patient Dosing in TWT-101, a Phase 1/2 Study of HPK1 Inhibitor, CFI-402411, in Patients with Solid...

Treadwell-Announces-Initiation-Expansion-Cohorts-Ongoing-Phase

by treadwell | Aug 27, 2020 | Uncategorized

Treadwell Announces Initiation of Expansion Cohorts in Ongoing Phase 1 Study of Oral TTK Inhibitor, CFI-402257, in Patients with Breast Cancer and Additional Solid...